PBA
EWTX icon

Paradigm Biocapital Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$415M Buy
10,215,455
+2,850,417
+39% +$98.3M 7.77% 3
2026
Q1 		$232M Buy
7,365,038
+823,828
+13% +$23.8M 4.74% 5
2025
Q4 		$162M Buy
6,541,210
+371,079
+6% +$7.45M 4.14% 11
2025
Q3 		$100M Buy
6,170,131
+27,787
+0.5% +$394K 2.85% 12
2025
Q2 		$80.5M Buy
6,142,344
+1,747,788
+40% +$25.2M 3.44% 8
2025
Q1 		$96.7M Sell
4,394,556
-99,373
-2% -$2.61M 4.43% 7
2024
Q4 		$120M Buy
4,493,929
+1,704,757
+61% +$54.3M 4.17% 7
2024
Q3 		$74.4M Buy
2,789,172
+463,723
+20% +$9.22M 2.52% 10
2024
Q2 		$41.9M Sell
2,325,449
-120,924
-5% -$2.11M 1.6% 20
2024
Q1 		$44.6M Buy
+2,446,373
New +$38.9M 1.57% 21

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Paradigm Biocapital Advisors's EWTX Position: Q2 2026 in Review

Paradigm Biocapital Advisors increased its Edgewise Therapeutics (EWTX) stake by 39% in Q2 2026, buying an estimated $98.3M and bringing the position to 10,215,455 shares worth $415M. The position accounts for 7.77% of the portfolio, ranked #3.

Paradigm Biocapital Advisors first reported a position in EWTX in Q1 2024 and has held it in 10 quarters since. 227 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Paradigm Biocapital Advisors held 10,215,455 shares of Edgewise Therapeutics worth $415M as of Q2 2026.
  • Paradigm Biocapital Advisors bought 2,850,417 Edgewise Therapeutics shares in Q2 2026, an estimated $98.3M.
  • Edgewise Therapeutics made up 7.77% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #3 holding.
  • Paradigm Biocapital Advisors first reported a position in Edgewise Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 227 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.